Nynomic (M7U) H2 2025 earnings summary

Executive summary

• Revenue declined 10% year-over-year to €92.6 million, with EBIT dropping 73% to €2.0 million, mainly due to restructuring costs and lower demand in key markets.

• The NyFIT2025 efficiency program led to temporary EBIT burdens but is expected to strengthen future profitability and cost structure.

• The company maintained a strong equity ratio of 75% and robust liquidity, with cash flow from operations at €7.5 million.

• Segment Clean Tech saw the largest revenue decline (-13%), while Green Tech remained stable and Life Science fell 9%.

• The group expects a return to profitable growth in 2026, targeting revenue of €100–105 million and an EBIT margin of 6–8%.

Financial highlights

• Revenue: €92.6 million (–10% YoY); EBIT: €2.0 million (–73% YoY); EBITDA: €7.9 million (–37% YoY).

• Net loss after minorities: €0.7 million; EPS: –€0.11 (after minorities).

• Cash flow from operations: €7.5 million; investments: €7.0 million; equity ratio: 75%.

• Personnel costs reduced by 4% to €41.2 million; average headcount down to 538.

• Regional sales: Europe –12%, America –19%, Asia +13%.

Outlook and guidance

• For 2026, revenue is forecast at €100–105 million with an EBIT margin of 6–8%.

• Management expects positive effects from restructuring and a return to growth, supported by a solid order backlog and improved cost base.

• Key growth drivers include digitalization, AI integration, and sustainability trends in core markets.